Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today a long-term extension of its collaboration with a major global biopharmaceutical partner ...

Lonza Group AG / Key word (s): Quarter Results Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024 24-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...

The acquisition of the large-scale mammalian manufacturing site complements Lonza’s ongoing investments in large-scale bioconjugation in Visp (CH) and drug product manufacturing in Stein (CH), ...

Lonza has boosted its ability to cater for customers ... which provides manufacturing services to the category from facilities in Visp, Switzerland. The group is paying €100 million ($107 ...

It will be built on the same campus as Lonza’s clinical drug product facility in Stein. The company also manufactures drugs in Basel and Visp, as well as in Guangzhou, China. Swiss food ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(RTTNews) - Lonza Group (LZAGF.PK), a Swiss manufacturer focused on the pharmaceutical and nutrition businesses, on Thursday reported that its third-quarter performance was in line to deliver on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss contract development and manufacturing organisation (CDMO) Lonza, part of a drive to match ...

Figures prepared in accordance with International Accounting Standards. Market value as of Oct. 23, 2023. © 2024 Fortune Media IP Limited. All Rights Reserved. Use ...